Daehwa to patent a direct injectable form of pacliataxel.

Daehwa pharmaceutical company announced on April 19 that the company completed a patent registration for a direct injectable form of pacliataxel into the bladder tumor sites, which is the first in such treatment for bladder cancer. So far, the bladder cancer has been treated with a surgical tumor removal, radiation, chemotherapy and immune therapy.

The preparation was designed for the water ...